Streetbeat News

Analyst Ratings

SCHW

Analysts have mixed views on Charles Schwab (NYSE:SCHW) with recent ratings showing a blend of bullish and bearish sentiments. The average 12-month price target has decreased by 5.41% to $74.78. Analysts have adjusted their ratings and price targets in response to market dynamics, with several lowering their targets. Despite challenges in revenue growth and returns, Schwab maintains a strong market position with a large market cap and efficient cost management.

Portfolio Pulse from Benzinga Insights

October 04, 2024 | 7:01 pm

RJF

Raymond James Financial (NYSE:RJF) has been evaluated by 7 analysts over the past three months, with most ratings being indifferent. The average 12-month price target is $130.71, slightly up from $129.50. Analysts have adjusted their ratings and price targets based on market conditions and company performance. RJF has shown a revenue growth rate of 10.92% and a net margin of 15.41%, but its ROA is below industry averages.

Portfolio Pulse from Benzinga Insights

October 04, 2024 | 7:01 pm

COHR

Coherent (NYSE:COHR) has received diverse evaluations from 15 analysts over the past three months, with a majority being bullish. The average 12-month price target has increased by 20.19% to $82.93. Analysts have raised their ratings and price targets, reflecting positive sentiment. Coherent's financial performance shows strong revenue growth and market position, but also highlights financial risks due to high debt levels.

Portfolio Pulse from Benzinga Insights

October 04, 2024 | 7:01 pm

GBTG

Citigroup analyst Peter Christiansen has maintained a Buy rating on Global Business Travel (NYSE:GBTG) and raised the price target from $9 to $9.5.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 7:00 pm

REGN

Over the past three months, 24 analysts have evaluated Regeneron Pharmaceuticals (NASDAQ:REGN), with a majority being somewhat bullish. The average 12-month price target has increased by 3.71% to $1194.29. Analysts have adjusted their ratings and price targets, reflecting their response to recent developments. Regeneron has shown strong financial performance with a notable net margin and ROE, despite lagging revenue growth compared to peers.

Portfolio Pulse from Benzinga Insights

October 04, 2024 | 7:00 pm

MPC

Analysts have mixed views on Marathon Petroleum (NYSE:MPC) with recent ratings showing a decrease in average price targets. Despite positive financial metrics, concerns about debt management persist.

Portfolio Pulse from Benzinga Insights

October 04, 2024 | 7:00 pm

ONON

On Holding shares are experiencing an upward trend following multiple analyst price target increases. This positive sentiment from analysts is likely driving the stock's current performance.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 6:58 pm

WMG

BofA Securities analyst Jessica Reif Ehrlich downgraded Warner Music Group (NASDAQ:WMG) from Neutral to Underperform, citing streaming volatility and execution risks. The price target was lowered from $33 to $30. Despite long-term growth potential, emerging platform disappointments and organizational changes pose risks.

Portfolio Pulse from Anusuya Lahiri

October 04, 2024 | 6:41 pm

NVO

Deep-pocketed investors are showing a bearish sentiment towards Novo Nordisk (NYSE:NVO) with significant options activity. The options scanner highlighted 20 extraordinary activities, with 50% of investors bearish. The stock is currently trading at $114.24, down by 0.73%. Analysts have set an average target price of $160.

Portfolio Pulse from Benzinga Insights

October 04, 2024 | 6:33 pm

ST

JP Morgan analyst Samik Chatterjee maintains an Underweight rating on Sensata Technologies and lowers the price target from $35 to $34.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 6:30 pm